Results 111 to 120 of about 10,516 (266)

Does DRD2 polymorphism influence the clinical characteristics of prolactinoma?

, 2015
Objectives. - Genetic alterations explaining the clinical variability of prolactinomas still could not be clarified and dopamine D2 receptor (DRD2) polymorphism is a putative candidate for the variable response to dopaminergic treatment.
Turgut, Seda, Turan, Saime, Yaylim, Ilhan, Zeybek, Umit, Shukurov, Samir, Ilhan, Muzaffer, TAŞAN, ERTUĞRUL, KARAMAN, ÖZCAN, Kahraman, Ozlem Timirci   +8 more
core   +1 more source

Nonalcoholic Fatty Liver Disease, Bone and Muscle Quality in Prolactinoma: A Pilot Study

Objective: Hyperprolactinemia has negative impacts on metabolism and musculoskeletal health. In this study, individuals with active prolactinoma were evaluated for nonalcoholic fatty liver disease (NAFLD) and musculoskeletal health, which are ...
Eroğlu, İmdat, Akata, Deniz, Erkoc, Aysegul, Yüce, Deniz, Iremli, Burcin Gonul, Çalık Kütükcü, Ebru, Erbas, Tomris, İdilman, İlkay Sedakat   +7 more
core   +1 more source

From guidelines to real daily practice: Prolactinoma in pregnancy

, 2016
Laurent Vroonen, Iulia Potorac, Settimio D’Andrea, Albert Beckers   +3 more
openalex   +2 more sources

Discrimination of prolactinoma from hyperprolactinemic non-functioning adenoma

, 2010
The objective of this study was to evaluate characteristics that discriminate prolactinoma from non-functioning pituitary macroadenoma with hyperprolactinemia. We included 117 patients with hyperprolactinemic pituitary macroadenomas.
이은직, 홍재원, 김선호
core   +1 more source

Cholesterol-activated stress granules reduce the membrane localization of DRD2 and promote prolactinoma dopamine agonists resistance

Acta Neuropathologica Communications
Prolactinoma is the most prevalent pituitary neuroendocrine tumor and dopamine agonists (DAs) targeting dopamine D2 receptor (DRD2) are recommended as the first-line treatment. However, varying degrees of DA resistance limit patient benefit.
Yuyang Peng, Huachun Yin, Xiangdong Pei, Yuan Zhang, Chengcheng Wang, Xin Zheng, Hong Liang, Hui Yang, Song Li   +8 more
doaj   +1 more source

Body fat in men with prolactinoma

, 2008
OBJECTIVE: (a) To evaluate body fat in men with prolactinoma and healthy controls, using whole body dual energy x-ray absorptiometry (DXA), and (b) to correlate DXA results with anthropometry and clinical aspects of male prolactinomas.
A. Lamounier Filho, E. C. Naliato, GACCIONE, MARIA, COLAO, ANNAMARIA, Y. Schrank, D. Caldas, C. R. Loureiro, A. H. Violante, R. Fontes, F. S. Costa   +9 more
core  

Clinical and Radiological Characteristics of a Patient with a Pituitary Tumor of the Prolactinoma Type — Case Report

Pielęgniarstwo Neurologiczne i Neurochirurgiczne
Introduction. Prolactinoma is a benign tumor of the anterior lobe of the pituitary gland. It is the most common type of pituitary adenoma. In terms of size, micro- and macroprolactinomas are distinguished.
Anna Krzentowska, Maria Smoter
doaj   +1 more source

Prolactinomas resistentes aos agonistas da dopamina: estudo de série de casos [PDF]

, 2016
Maria de Fátima de Magalhães Gonzaga
openalex   +1 more source

In vivo detection of ifosfamide by 31P-MRS in rat tumours: increased uptake and cytotoxicity induced by carbogen breathing in GH3 prolactinomas [PDF]

, 1997
Luís Monteiro Rodrigues, RJ Maxwell, PMJ McSheehy, CR Pinkerton, Simon P. Robinson, Marion Stubbs, JR Griffiths   +6 more
openalex   +1 more source

Morbid Obesity Due to Prolactinoma and Significant Weight Loss After Dopamine Agonist Treatment

, 2021
Muzaffar Ali, Lubna Mirza
openalex   +1 more source